TW202321261A - 選擇性ｋｒａｓ抑制劑 - Google Patents

選擇性ｋｒａｓ抑制劑 Download PDF

Info

Publication number
TW202321261A
TW202321261A TW111129927A TW111129927A TW202321261A TW 202321261 A TW202321261 A TW 202321261A TW 111129927 A TW111129927 A TW 111129927A TW 111129927 A TW111129927 A TW 111129927A TW 202321261 A TW202321261 A TW 202321261A
Authority
TW
Taiwan
Prior art keywords
alkyl
mmol
carcinoma
tumor
fluoro
Prior art date
Application number
TW111129927A
Other languages
English (en)
Chinese (zh)
Inventor
恒淼 程
尚米榭 凡尼爾
璞慧 李
Original Assignee
美商伊瑞斯卡公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商伊瑞斯卡公司 filed Critical 美商伊瑞斯卡公司
Publication of TW202321261A publication Critical patent/TW202321261A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111129927A 2021-08-10 2022-08-09 選擇性ｋｒａｓ抑制劑 TW202321261A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163231592P 2021-08-10 2021-08-10
US63/231,592 2021-08-10
US202163291855P 2021-12-20 2021-12-20
US63/291,855 2021-12-20
US202263364141P 2022-05-04 2022-05-04
US63/364,141 2022-05-04

Publications (1)

Publication Number Publication Date
TW202321261A true TW202321261A (zh) 2023-06-01

Family

ID=83149037

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111129927A TW202321261A (zh) 2021-08-10 2022-08-09 選擇性ｋｒａｓ抑制劑

Country Status (3)

Country Link
EP (1) EP4384522A1 (de)
TW (1) TW202321261A (de)
WO (1) WO2023018699A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024008179A1 (en) * 2022-07-07 2024-01-11 Beigene, Ltd. Heterocyclic compounds, compositions thereof, and methods of treatment therewith
CN117263959A (zh) * 2022-10-24 2023-12-22 药雅科技(上海)有限公司 芳香类kras突变蛋白抑制剂的制备及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
CA2216796C (en) 1995-03-30 2003-09-02 Pfizer Inc. Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
SK398A3 (en) 1995-07-06 1998-07-08 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
PL340800A1 (en) 1997-11-06 2001-02-26 American Cyanamid Co Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
US11453683B1 (en) * 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022061251A1 (en) * 2020-09-18 2022-03-24 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
US20240140957A1 (en) * 2021-01-08 2024-05-02 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
TWI810803B (zh) * 2021-03-15 2023-08-01 大陸商藥雅科技（上海）有限公司 突變蛋白抑制劑的製備及其應用

Also Published As

Publication number Publication date
WO2023018699A1 (en) 2023-02-16
EP4384522A1 (de) 2024-06-19

Similar Documents

Publication Publication Date Title
EP3218375B1 (de) Sustituierte pyrrolopyridine als bromodomain-hemmer
US10150767B2 (en) Therapeutic compounds and uses thereof
EP4067347B1 (de) Heterocyclische inhibitoren von cbp/ep300 zur behandlung von krebs
TW202321261A (zh) 選擇性ｋｒａｓ抑制劑
WO2016138114A1 (en) Therapeutic pyridazine compounds and uses thereof
WO2022221386A1 (en) Selective kras inhibitors
WO2013078254A1 (en) Bicyclic heteroaryl derivatives as kinase inhibitors
TW202317198A (zh) Ｋｒａｓ抑制劑結合物
EP3250571B1 (de) Therapeutische verbindunegn und deren verwendung
US10358437B2 (en) Therapeutic compounds and uses thereof
WO2022271658A1 (en) Tricyclic kras inhibitors
WO2022266069A1 (en) Tricyclic kras g12d inhibitors
WO2022265974A1 (en) Aminoheterocycle-substituted tricyclic kras inhibitors
AU2021204704B2 (en) Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
WO2015049325A1 (en) Therapeutic inhibitors of cdk8 and uses thereof
EP4347603A1 (de) Schwefelhaltige heteroaromatische tricyclische kras-hemmer
WO2022266167A1 (en) Amide and urea-containing tricyclic kras inhibitors
EP3242872B1 (de) (piperidin-3-yl)(naphthalen-2-yl)methanon-derivate und verwandte verbindungen als inhibitoren der histon demethylase kdm2b zur behandlung von krebs
JP2019518032A (ja) Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
CN118076612A (zh) 含硫杂芳族三环kras抑制剂
WO2024040080A1 (en) Kras inhibitor conjugates
TW202400609A (zh) 三環吡啶酮及嘧啶酮